P-93 PREVALENCE OF HEPATITIS E VIRUS IN DIFFERENT GROUPS OF PATIENTS IN SALVADOR, BA, BRAZIL

Abstract

Few studies have been published to assess the prevalence of HEV in our country. To determine the prevalence of HEV in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), autoimmune hepatitis (HAI) and in patients with drug-induced liver injury (DILI). This is a cross-sectional study. A total of 300 volunteers were recruited at the Magalhães Neto Ambulatory, HUPES. Detection of anti-HEV antibodies was determined using the Mikrogen® ELISA (RecomWell anti-HEV IgG, Mikrogen®, Germany). Descriptive statistics was used. 46% (138/300) had HBV, 35.3% (106/300) HCV, 12.3% (37/300) HAI and 6.3% (19/300). The prevalence of anti-HEV IgG was 12.43%, after stratification of patient groups we observed a prevalence of anti-HEV IgG of 13.7% in patients with HCV, 12.9% of HBV, 6.7% of HAI and 21%. The means of TGO and TGP among patients VHE negative were 60.5 and 65.7 IU / mL, respectively, while the mean among those seropositive for HEV were 75.8 and 104.9 IU / mL, respectively, demonstrating an increase in the levels of TGO and TGP among HEV positive people. The mean TGP among DILI patients was 993.3 IU / mL and TGO was 641.4 IU / mL. Fibrosis staging among seropositive individuals was F1 in 21.7%, F2 in 42.2%, F3 in 27.2 and F4 8.9. In this sample, there was a higher prevalence of HEV among patients with DILI but the number is small, the levels of TGO and TGP were higher and fibrosis was more accentuated among patients with hepatitis E. This data suggest that infection with HEV may cause a worsening in the clinical condition of patients.